Patents by Inventor Mei-Mei Tsai

Mei-Mei Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10981999
    Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 20, 2021
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Patent number: 10835915
    Abstract: Disclosed is an essence atomizer having an integrally formed universal connector, comprising: an atomizer universal connector integrally formed into a pipe piece, and an outer shell. Wherein, the pipe port of the first end portion is greater than the pipe port of the second end portion. On the pipe port of the first end portion is disposed inward in sequence a front connection port, the inner threads, and a bottom groove for placing a rubber ring. While on the pipe port of the second end portion is disposed an expansion ring connected to an atomizer plate, an oil prevention pad, and a nozzle cover. The essence atomizer is compact in size and simple in structure Since the essence atomizer is integrally formed into a piece, so it requires less components, and the production process can be reduced.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: November 17, 2020
    Inventors: Hsuan-Yu Chao, Mei-Mei Tsai
  • Publication number: 20200009599
    Abstract: Disclosed is an essence atomizer having an integrally formed universal connector, comprising: an atomizer universal connector integrally formed into a pipe piece, and an outer shell. Wherein, the pipe port of the first end portion is greater than the pipe port of the second end portion. On the pipe port of the first end portion is disposed inward in sequence a front connection port, the inner threads, and a bottom groove for placing a rubber ring. While on the pipe port of the second end portion is disposed an expansion ring connected to an atomizer plate, an oil prevention pad, and a nozzle cover. The essence atomizer is compact in size and simple in structure Since the essence atomizer is integrally formed into a piece, so it requires less components, and the production process can be reduced.
    Type: Application
    Filed: July 3, 2018
    Publication date: January 9, 2020
    Inventors: HSUAN-YU CHAO, MEI-MEI TSAI
  • Publication number: 20190256605
    Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Application
    Filed: March 5, 2019
    Publication date: August 22, 2019
    Applicant: AMGEN INC.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Patent number: 10266598
    Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: April 23, 2019
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Patent number: 10227406
    Abstract: This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: March 12, 2019
    Assignee: AMGEN, INC
    Inventors: Peter Coward, Steven A. Moore, Jr., Shi-Yuan Meng, Mei-Mei Tsai, Chadwick Terence King, Aaron Avraham Nazarian
  • Patent number: 10035861
    Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: July 31, 2018
    Assignee: Amgen Inc.
    Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
  • Patent number: 9708375
    Abstract: The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 18, 2017
    Assignee: Amgen Inc.
    Inventors: Ryan B. Case, Benjamin M. Alba, Alice Bakker, Irwin Chen, Amy N. Duguay, Monica Florio, Peng Li, Mark Leo Michaels, Mei-Mei Tsai
  • Patent number: 9688756
    Abstract: Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 27, 2017
    Assignee: AMGEN INC.
    Inventors: Jeonghoon Sun, Seog Joon Han, Susie M Harris, Randal R Ketchem, Ji Lu, Mark L Michaels, Marc W Retter, Mei-Mei Tsai
  • Publication number: 20170107288
    Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Application
    Filed: August 25, 2016
    Publication date: April 20, 2017
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Patent number: 9623137
    Abstract: An essential oil diffuser comprises a main body and a power plug. The main body includes a shell, an electric circuit board, a connector shell, and an ultrasonic vibration module. Wherein, a receiving room is formed in the shell, an opening is formed at one end of the shell, and a shell hole is disposed on an upper shell. The connector shell is provided in the receiving room on a side of the shell opening. A receiving room is also formed in the connector shell, to receive an essence container screwed therein. The ultrasonic vibration module is disposed in the receiving room of the connector shell, and it is provided with an atomized liquid outlet corresponding to the shell hole and the connector hole, and is sleeved in the connector shell by means of a sleeve piece.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: April 18, 2017
    Inventors: Hsuan-Yu Chao, Mei-Mei Tsai
  • Patent number: 9453080
    Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: September 27, 2016
    Assignee: AMGEN INC.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • Publication number: 20160145333
    Abstract: This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.
    Type: Application
    Filed: June 25, 2014
    Publication date: May 26, 2016
    Applicant: AMGEN INC.
    Inventors: Peter COWARD, Steven A. MOORE, Jr., Shi-Yuan MENG, Mei-Mei TSAI, Chadwick Terence KING, Aaron Avraham NAZARIAN
  • Publication number: 20160107186
    Abstract: An essential oil diffuser comprises a main body and a power plug. The main body includes a shell, an electric circuit board, a connector shell, and an ultrasonic vibration module. Wherein, a receiving room is formed in the shell, an opening is formed at one end of the shell, and a shell hole is disposed on an upper shell. The connector shell is provided in the receiving room on a side of the shell opening. A receiving room is also formed in the connector shell, to receive an essence container screwed therein. The ultrasonic vibration module is disposed in the receiving room of the connector shell, and it is provided with an atomized liquid outlet corresponding to the shell hole and the connector hole, and is sleeved in the connector shell by means of a sleeve piece.
    Type: Application
    Filed: October 6, 2015
    Publication date: April 21, 2016
    Inventors: Hsuan-Yu Chao, Mei-Mei Tsai
  • Publication number: 20160024158
    Abstract: The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Ryan B. CASE, Benjamin M. ALBA, Alice BAKKER, Irwin CHEN, Amy N. DUGUAY, Monica FLORIO, Peng LI, Mark Leo MICHAELS, Mei-mei TSAI
  • Publication number: 20150274829
    Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
    Type: Application
    Filed: November 24, 2014
    Publication date: October 1, 2015
    Inventors: Frank J. CALZONE, Rajendra V. DESHPANDE, Mei-Mei TSAI
  • Publication number: 20150152194
    Abstract: This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Application
    Filed: June 11, 2013
    Publication date: June 4, 2015
    Inventors: Huiquan Han, Xiolan Zhou, Qing Chen, Mei-Mei Tsai
  • Publication number: 20140356358
    Abstract: Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.
    Type: Application
    Filed: December 17, 2012
    Publication date: December 4, 2014
    Inventors: Jeonghoon Sun, Seog Joon Han, Susie M. Harris, Randal R Ketchem, Ji Lu, Mark L Michaels, Marc W Retter, Mei-Mei Tsai
  • Patent number: 8895008
    Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: November 25, 2014
    Assignee: Amgen Inc.
    Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
  • Patent number: 8541201
    Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: September 24, 2013
    Assignee: Amgen Inc.
    Inventors: Hosung Min, Kenneth W. Walker, Colin V. Gegg, Francesco Galimi, Jeonghoon Sun, Mei-Mei Tsai